Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Clinical Trials: The Engine of Medical Progress & Innovation
From James Lind to modern decentralized models: explore how clinical trials drive the drug development process, regulatory agility, and global public health.
FDA Approves New 2g Fibryga Formulation for AFD
Octapharma receives FDA approval for a new 2g Fibryga kit. Discover how this human plasma-derived fibrinogen concentrate improves haemostasis in urgent care.
Iza-Bren (EGFR×HER3 ADC): New Precision Cancer Treatment
Learn about Iza-Bren (BL-B01D1), a breakthrough bispecific ADC by SystImmune & BMS targeting EGFR and HER3 for lung and nasopharyngeal cancer treatment.
Novel Small Molecule Inhibitors in Endometrial Cancer: Phase 2b Results
Prexasertib (ACR-368) shows 67% ORR in serous endometrial cancer. Explore the latest Phase 2b trial data, AP3 platform insights, and ACR-2316 development.
VectorY VTx-002 Earns FDA Fast Track for ALS Therapy
VectorY Therapeutics receives FDA Fast Track status for VTx-002, a vectorized antibody targeting TDP-43 to treat Amyotrophic Lateral Sclerosis (ALS).
Sepsis Care Breakthrough: Procalcitonin Tests Save Lives
University of Manchester researchers prove procalcitonin blood tests safely reduce antibiotic use in sepsis patients by two days, fighting resistance.
Merck in Talks to Acquire Revolution Medicines for $30B
Merck & Co. explores a potential $28-$32 billion acquisition of Revolution Medicines to bolster its oncology pipeline with targeted RAS inhibitors.
TMZ & EdU Combination Therapy
UNC researchers discover a synergistic combination of TMZ and EdU that kills glioblastoma cells while sparing healthy tissue. A potential shift in brain cancer R&D.
Clinical Trials in Indonesia: Strengthening the Ecosystem 2025
Indonesia partners with WHO to expand clinical trial capacity. Learn about the 83% growth in research activity and the new 2026-2027 roadmap for global trials.
The FDA Reform Test: Deregulation vs. Rare Disease Pathways
Exploring the FDA's 2025 reforms under HHS leadership. Will new pathways for PDCD and DCA lead to genuine deregulation or regulatory capture?
FDA Approves Mitapivat: First Oral Pill for Thalassemia
US FDA approves mitapivat (Aqvesme), the first oral pyruvate kinase activator for alpha- and beta-thalassemia. A breakthrough in treating chronic anemia.
Valneva Resumes Control of Ixchiq Vaccine Supply in Asia
Valneva terminates license agreement with Serum Institute of India (SII) to take direct control of Ixchiq chikungunya vaccine supply and commercialization.
35
36
37
38
39
40
41
42
43
